Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Velcade’s New SubQ Formulation Means More To Takeda Than An Incremental Advance

This article was originally published in The Pink Sheet Daily

Executive Summary

Market leading multiple myeloma treatment Velcade’s newly approved subcutaneous formulation offers greatly reduced rates of peripheral neuropathy compared to the standby intravenous formula and with similar survival data, a new marketing advantage in the face of next-generation challenges.

Advertisement

Related Content

Takeda’s Weekly Oral Proteasome Inhibitor Ixazomib Passes First Pivotal Test
Takeda’s Weekly Oral Proteasome Inhibitor Ixazomib Passes First Pivotal Test
With Kyprolis Advancing, Millennium Stakes Faith In Oral Velcade Successor
FDA Accepts Onyx’s Carfilzomib Application But Denies Priority Review
Millennium Withdraws Velcade Follicular Lymphoma sNDA, Citing Business Decision
Seattle Genetics Will Test Oncology Pricing Acceptance With Adcetris
The Next Big Thing In Drug Development May Be The Ubiquitin Pathway
Market Snapshot: Multiple Myeloma Drugs Promise To Live Up To Hype
Takeda Partners With Seattle Genetics On Lymphoma Candidate In Pivotal Trials
Carfilzomib Multiple Myeloma Data Do New Onyx Parent Proud At ASH '09

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS073291

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel